Status:
TERMINATED
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breas...
Eligibility Criteria
Inclusion
- Have been diagnosed with metastatic or recurrent breast cancer.
- Have been previously treated with both an anthracycline and a taxane.
- Have not received more than two prior chemotherapy treatment programs.
- Have stopped any antitumoral hormonal treatment before you enroll in this study.
- Have a negative pregnancy blood test if menstruating or capable of becoming pregnant. You must use an approved birth control method during the study and for 3 months after stopping study treatment.
Exclusion
- Cannot follow the study procedures (for example, you cannot swallow tablets).
- Are receiving another treatment for your cancer.
- Have received another experimental drug in the last 4 weeks.
- Have had serious heart disease within last 6 months.
- Are pregnant or breast-feeding.
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00437294
Start Date
March 1 2007
End Date
March 1 2009
Last Update
August 10 2020
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buenos Aires, Argentina, 1430
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Resistencia, Argentina, 3500
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tucumain, Argentina, 4000
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Garran, Australian Capital Territory, Australia, 2605